Jasper Therapeutics, Inc. (JSPR) stock
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.37−1.39 (-9.42%)
Close on Nov 12, 2026Market cap $444.88MP/E –Yield –
Jasper Therapeutics cash
Cash and short-term investments held at the end of each period.
Jasper Therapeutics's cash was $7.31M at Jun 30, 2026. For fiscal 2025 it was $28.69M, down 60.2% from the year before. The highest annual figure on record is $87.30M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.69M | -60.2% |
| FY2024 | Dec 31, 2024 | $72.05M | -17.5% |
| FY2023 | Dec 31, 2023 | $87.30M | +125.8% |
| FY2022 | Dec 31, 2022 | $38.67M | -54.5% |
| FY2021 | Dec 31, 2021 | $85.05M | +321.4% |
| FY2020 | Dec 31, 2020 | $20.18M | -25.7% |
| FY2019 | Dec 31, 2019 | $27.16M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.31M | -81.7% |
| Q1 FY2026 | Mar 31, 2026 | $14.14M | -71.3% |
| Q4 FY2025 | Dec 31, 2025 | $28.69M | -60.2% |
| Q3 FY2025 | Sep 30, 2025 | $50.90M | -45.2% |
| Q2 FY2025 | Jun 30, 2025 | $39.93M | -62.8% |
| Q1 FY2025 | Mar 31, 2025 | $49.22M | -58.6% |
| Q4 FY2024 | Dec 31, 2024 | $72.05M | -17.5% |
| Q3 FY2024 | Sep 30, 2024 | $92.92M | -22.2% |
| Q2 FY2024 | Jun 30, 2024 | $107.24M | -17.4% |
| Q1 FY2024 | Mar 31, 2024 | $118.89M | +207.5% |
| Q4 FY2023 | Dec 31, 2023 | $87.30M | +70.0% |
| Q2 FY2023 | Jun 30, 2023 | $119.43M | +95.0% |
| Q1 FY2023 | Mar 31, 2023 | $129.82M | +83.3% |
| Q4 FY2022 | Dec 31, 2022 | $38.67M | -54.5% |
| Q3 FY2022 | Sep 30, 2022 | $51.37M | -49.3% |
| Q2 FY2022 | Jun 30, 2022 | $61.23M | +258.0% |
| Q1 FY2022 | Mar 31, 2022 | $70.82M | +197.8% |
| Q4 FY2021 | Dec 31, 2021 | $85.05M | +321.4% |
| Q3 FY2021 | Sep 30, 2021 | $101.25M | +585.4% |
| Q2 FY2021 | Jun 30, 2021 | $17.10M | +1770.6% |
| Q1 FY2021 | Mar 31, 2021 | $23.78M | +2149.3% |
| Q4 FY2020 | Dec 31, 2020 | $20.18M | -25.7% |
| Q3 FY2020 | Sep 30, 2020 | $14.77M | – |
| Q2 FY2020 | Jun 30, 2020 | $914.25K | – |
| Q1 FY2020 | Mar 31, 2020 | $1.06M | – |
| Q4 FY2019 | Dec 31, 2019 | $27.16M | – |
See a number that looks wrong?